Literature DB >> 10679300

Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon.

R Mineo1, E Fichera, S J Liang, Y Fujita-Yamaguchi.   

Abstract

Upregulation of insulin-like growth factor (IGF)-II expression has been reported for a variety of childhood and adulthood tumors. We determined IGF-II gene promoter usage in human cancerous and benign tissues by semiquantitative RT-PCR using P1-P4-specific primers. Although the human IGF-II gene structure is commonly thought to consist of nine exons and four promoters, we detected substantial utilization of a previously reported exon 4b, which is downstream of exon 4. Thus, exon 4b was intensively studied using 4b-specific primers. IGF-II gene promoter usage is highly variable in malignant and benign breast, prostate, and bladder tissues. While a majority of samples utilized P2-P4 promoters in a variety of combinations, when quantitated, P3 and P4 promoters were much more active than P2 promoter. This study not only demonstrated that IGF-II gene promoter usage is highly variable in malignant and benign tissues, but suggested that alternatively spliced exon 4b should be recognized as a 10th exon. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679300     DOI: 10.1006/bbrc.2000.2225

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Insulin-like growth factor II mediates resveratrol stimulatory effect on cathepsin D in breast cancer cells.

Authors:  Sharda Vyas; Yayesh Asmerom; Daisy D De León
Journal:  Growth Factors       Date:  2006-03       Impact factor: 2.511

2.  Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2012-08-22

3.  Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Tatiana Birman; Ofer N Gofrit; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2011-04-30

4.  IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics.

Authors:  Biyun Qian; Dionyssios Katsaros; Lingeng Lu; Emilie Marion Canuto; Chiara Benedetto; Alicia Beeghly-Fadiel; Herbert Yu
Journal:  Oncol Rep       Date:  2011-01       Impact factor: 3.906

5.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

6.  Evidence that Igf2 down-regulation in postnatal tissues and up-regulation in malignancies is driven by transcription factor E2f3.

Authors:  Julian C Lui; Jeffrey Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

7.  IGF-II promoter methylation and ovarian cancer prognosis.

Authors:  A C Beeghly; D Katsaros; A L Wiley; I A Rigault de la Longrais; A T Prescott; H Chen; M Puopolo; T J Rutherford; H Yu
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-14       Impact factor: 4.553

8.  Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Abraham Hochberg
Journal:  J Transl Med       Date:  2010-12-16       Impact factor: 5.531

Review 9.  The IGF-II-Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives.

Authors:  Pierluigi Scalia; Antonio Giordano; Stephen J Williams
Journal:  Cancers (Basel)       Date:  2020-02-05       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.